MyFinsight
Home
Blog
About
Maturities/sales of short-term
investments
$28,750K
(33.55%↑ Y/Y)
Proceeds from issuance of
common stock under...
$259K
Proceeds from exercises
of common stock...
$3K
(-97.41%↓ Y/Y)
Net cash provided by
(used in) investing...
$28,750K
(127.85%↑ Y/Y)
Net cash provided by
financing activities
$262K
(-99.70%↓ Y/Y)
Net increase
(decrease) in cash and cash...
$11,413K
(132.02%↑ Y/Y)
Canceled cashflow
$17,599K
Stock-based compensation
expense
$1,950K
(124.91%↑ Y/Y)
Prepaid expenses and
other assets
-$146K
(-103.41%↓ Y/Y)
Non-cash lease expense
$89K
(-58.22%↓ Y/Y)
Depreciation expense
$11K
(-31.25%↓ Y/Y)
Net cash used in
operating activities
-$17,599K
(17.11%↑ Y/Y)
Canceled cashflow
$2,196K
Net loss
-$14,387K
(39.24%↑ Y/Y)
Accrued liabilities
-$2,875K
(-189.37%↓ Y/Y)
Accounts payable
-$2,407K
(-174.68%↓ Y/Y)
Operating lease liability
-$105K
(21.64%↑ Y/Y)
Amortization of discount on
short-term investments
$19K
(-97.29%↓ Y/Y)
Unrealized loss on
short-term investments
$2K
(109.09%↑ Y/Y)
Back
Back
Cash Flow
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)
source: myfinsight.com